新型冠状病毒感染相关心肌损伤、心肌炎和感染后状态管理专家共识（第二版）

doi:10.12114/j.issn.1007-9572.2023.0083

中国全科医学 ›› 2023, Vol. 26 ›› Issue (14): 1692-1702.DOI: 10.12114/j.issn.1007-9572.2023.0083

所属专题： COVID-19疫情防控研究；指南/共识最新文章合辑；新型冠状病毒肺炎最新文章合辑

新型冠状病毒感染相关心肌损伤、心肌炎和感染后状态管理专家共识（第二版）

国家老年医学中心, 中国老年医学学会心电与心功能分会, 北京医学会心血管病学分会影像学组, 中国医药卫生文化协会心血管健康与科学运动分会

收稿日期:2023-01-30 修回日期:2023-02-17 出版日期:2023-05-15 发布日期:2023-02-24
本文首先发表在《中国循环杂志》2023年第38卷第2期第105~115页，发表时间2023-02-24
基金资助:
国家重点研发计划项目(2020YFC2008100)

Expert Consensus for Management of Myocardial Injury, Myocarditis, and Post-infection Condition with Coronavirus Disease 2019 (Second Edition)

National Center of Gerontology, Electrocardiology and Cardiac Function Branch of Chinese Geriatric Society, Imaging Group of Cardiovascular Department, Beijing Medical Association, Chinese Medical and Health Culture Association Cardiovascular Health and Science Sports Branch of China Health Culture Association

Received:2023-01-30 Revised:2023-02-17 Published:2023-05-15 Online:2023-02-24

摘要/Abstract

摘要： 新型冠状病毒感染（COVID-19）已被证实可累及全身多个系统，其中心血管系统受累很常见。为帮助临床医师合理诊治COVID-19相关心血管问题，共识组建议：（1）对于因COVID-19住院或伴有心脏相关症状的患者，应常规检测心肌肌钙蛋白，以评估心肌损伤，判断有无心脏并发症；非心脏原因所致心肌损伤的患者预后较差；（2）COVID-19相关急性心肌炎较为罕见，对怀疑心肌炎的患者应根据危险分层进行诊治；（3）COVID-19可增加心血管事件风险，所有感染者应更加严格遵循健康生活方式，接受规范的心血管疾病一级或二级预防；（4）COVID-19后3个月时有持续心脏相关症状或新发相关症状，且至少持续2个月，但心血管相关检查未见异常，可考虑为"COVID-19后状态"，此类患者应以康复治疗为主。

关键词: 新型冠状病毒感染, 心肌疾病, 心肌损伤, 心肌炎, 新型冠状病毒感染后状态, 专家共识, 指南

Abstract:

Evidence shows that coronavirus disease 2019 (COVID-19) can impact multiple bodily systems, with the cardiovascular system being commonly affected. In order to guide healthcare providers in diagnosing and managing cardiovascular issues related to COVID-19, the consensus group recommends: (1) Routine cardiac troponin testing is necessary for patients who are hospitalized or exhibit symptoms related to heart conditions after COVID-19 infection to evaluate potential myocardial injury and help detect any cardiac complications. Patients with myocardial injury not related to heart issues tend to have a poorer outcome. (2) Relatively few cases of acute myocarditis linked to COVID-19 have been reported, and individuals suspected of having myocarditis should be evaluated and managed based on risk stratification. (３) COVID-19 infection should be considered a risk factor for increasing the incidence of cardiovascular disease. All individuals who have been infected should adhere to a healthy lifestyle more strictly and implement appropriate primary or secondary preventive measures for cardiovascular disease. (4) For individuals who experience the persistence or emergence of new symptoms 3 months after the initial COVID-19 infection and have been experiencing these symptoms for at least 2 months, with no clear diagnosis of a cardiovascular disease through standard diagnostic tests, it is advisable to consider the possibility of "post COVID-19 condition". Rehabilitation should be given top priority for these patients.

Key words: COVID-19, Cardiomyopathies, Myocardial injury, Myocarditis, Post COVID-19 condition, Expert consensus, Guidebook

国家老年医学中心,中国老年医学学会心电与心功能分会,北京医学会心血管病学分会影像学组,等. 新型冠状病毒感染相关心肌损伤、心肌炎和感染后状态管理专家共识（第二版）[J]. 中国全科医学, 2023, 26(14): 1692-1702. DOI: 10.12114/j.issn.1007-9572.2023.0083.
National Center of Gerontology,Electrocardiology and Cardiac Function Branch of Chinese Geriatric Society,Imaging Group of Cardiovascular Department, Beijing Medical Association, et al. Expert Consensus for Management of Myocardial Injury, Myocarditis, and Post-infection Condition with Coronavirus Disease 2019 (Second Edition)[J]. Chinese General Practice, 2023, 26(14): 1692-1702. DOI: 10.12114/j.issn.1007-9572.2023.0083.

图/表 2

表1 COVID-19患者发生急性心血管事件和心肌损伤的常见原因[9]

Table 1 Causes of acute cardiac events and myocardial injury in COVID-19 patients

项目

具体原因

心脏原因

（1）1型心肌梗死（包括STEMI和NSTEMI）；（2）2型心肌梗死（冠状动脉痉挛、冠状动脉栓塞、自发性冠状动脉夹层）；（3）急性心肌损伤〔多数情况下心肌肌钙蛋白稳定或不变、COVID-19直接损伤（罕见）、其他疾病所致的间接损伤〕；（4）冠状动脉正常或接近正常的急性冠脉综合征；（5）心肌炎；（6）冠状动脉炎；（7）急性心力衰竭；（8）急性心律失常

非心脏原因

（1）肺栓塞；（2）危重疾病；（3）低氧血症；（4）败血症；（5）休克；（6）贫血；（7）肾脏疾病

图1 疑似心肌炎或心脏受累患者的评估和处理流程注：a提示心脏受累的症状包括胸痛、呼吸困难、心悸和晕厥；b说明ECG若出现广泛导联ST-T改变、QRS波显著延长、窦性停搏和高度房室阻滞，提示心肌损伤严重；c表示常呈非冠状动脉分布，也可能包括异常心室应变；d包括低血压、心原性休克、持续性室性心律失常和/或高度房室传导阻滞；e表示这是一个不完整的潜在病因列表；f提示如果可能的话，应在冷冻心脏组织上进行病毒基因组检测，以排除心肌炎的其他原因；g表示假设胸痛为唯一症状，左心室收缩功能保留，无室性心律失常；h包括ECG、超声心动图、动态心律监测和CMR。COVID-19=新型冠状病毒感染，ECG=心电图，cTn=心肌肌钙蛋白，CTA=计算机断层扫描血管造影，PCT=降钙素原，LVEF=左心室射血分数，CMR=心脏磁共振成像

Figure 1 Evaluation and management of patients with suspected myocarditis or myocardial involvement

参考文献 74

[1]	GLUCKMAN T J，BHAVE N M，ALLEN L A，et al. 2022 ACC expert consensus decision pathway on cardiovascular sequelae of COVID-19 in adults:myocarditis and other myocardial involvement，post-acute sequelae of SARS-CoV-2 infection，and return to play：a report of the American College of Cardiology Solution Set Oversight Committee[J]. J Am Coll Cardiol，2022，79（17）：1717-1756. DOI：10.1016/j.jacc.2022.02.003.
[2]	CAFORIO A L，PANKUWEIT S，ARBUSTINI E，et al. Current state of knowledge on aetiology，diagnosis，management，and therapy of myocarditis:a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases[J]. Eur Heart J，2013，34（33）：2636-2648，2648a-2648d. DOI：10.1093/eurheartj/eht210.
[3]	AMMIRATI E，LUPI L，PALAZZINI M，et al. Prevalence，characteristics，and outcomes of COVID-19-associated acute myocarditis[J]. Circulation，2022，145（15）：1123-1139. DOI：10.1161/CIRCULATIONAHA.121.056817.
[4]	国家老年医学中心/国家老年疾病临床医学研究中心，中国老年医学学会心血管病分会，北京医学会心血管病学会影像学组. 新型冠状病毒肺炎相关心肌损伤的临床管理专家建议（第一版）[J]. 中国循环杂志，2020，35（4）：326-330. DOI：10.3969/j.issn.1000-3614.2020.04.002.
[5]	HUANG C L，WANG Y M，LI X W，et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan，China[J]. Lancet，2020，395（10223）：497-506. DOI：10.1016/S0140-6736(20)30183-5.
[6]	CHIMENTI C，MAGNOCAVALLO M，BALLATORE F，et al. Prevalence and clinical implications of COVID-19 myocarditis[J]. Card Electrophysiol Clin，2022，14（1）：53-62. DOI：10.1016/j.ccep.2021.11.001.
[7]	ABATE S M，MANTEFARDO B，NEGA S，et al. Global burden of acute myocardial injury associated with COVID-19:a systematic review，meta-analysis，and meta-regression[J]. Ann Med Surg（Lond），2021，68：102594. DOI：10.1016/j.amsu.2021.102594.
[8]	LI X T，GUAN B，SU T，et al. Impact of cardiovascular disease and cardiac injury on in-hospital mortality in patients with COVID-19:a systematic review and meta-analysis[J]. Heart，2020，106（15）：1142-1147. DOI：10.1136/heartjnl-2020-317062.
[9]	MANOLIS A S，MANOLIS A A，MANOLIS T A，et al. COVID-19 and acute myocardial injury and infarction: related mechanisms and emerging challenges[J]. J Cardiovasc Pharmacol Ther，2021，26（5）：399-414. DOI：10.1177/10742484211011026.
[10]	KHALOO P，SHAQDAN A，LEDESMA P A，et al. Distinct etiologies of high-sensitivity troponin T elevation predict different mortality risks for patients hospitalized with COVID-19[J]. Int J Cardiol，2022，351：118-125. DOI：10.1016/j.ijcard.2021.12.029.
[11]	HENDREN N S，DRAZNER M H，BOZKURT B，et al. Description and proposed management of the acute COVID-19 cardiovascular syndrome[J]. Circulation，2020，141（23）：1903-1914. DOI：10.1161/CIRCULATIONAHA.120.047349.
[12]	HELMS J，COMBES A，AISSAOUI N. Cardiac injury in COVID-19[J]. Intensive Care Med，2022，48（1）：111-113. DOI：10.1007/s00134-021-06555-3.
[13]	BULL T M，CLARK B，MCFANN K，et al. Pulmonary vascular dysfunction is associated with poor outcomes in patients with acute lung injury[J]. Am J Respir Crit Care Med，2010，182（9）：1123-1128. DOI：10.1164/rccm.201002-0250OC.
[14]	CHENG M P，CAU A，LEE T C，et al. Acute cardiac injury in coronavirus disease 2019 and other viral infections-a systematic review and meta-analysis[J]. Crit Care Med，2021，49（9）：1558-1566. DOI：10.1097/CCM.0000000000005026.
[15]	HALUSHKA M K，VANDER HEIDE R S. Myocarditis is rare in COVID-19 autopsies: cardiovascular findings across 277 postmortem examinations[J]. Cardiovasc Pathol，2021，50：107300. DOI：10.1016/j.carpath.2020.107300.
[16]	AKWE J，HALFORD B，KIM E，et al. A review of cardiac and non-cardiac causes of troponin elevation and clinical relevance part II:non cardiac causes[J]. J Cardiol Curr Res，2018，11（1）：00364. DOI：10.15406/jccr.2018.11.00364.
[17]	GAZE D C. Clinical utility of cardiac troponin measurement in COVID-19 infection[J]. Ann Clin Biochem，2020，57（3）：202-205. DOI：10.1177/0004563220921888.
[18]	XIE Y，XU E，BOWE B，et al. Long-term cardiovascular outcomes of COVID-19[J]. Nat Med，2022，28（3）：583-590. DOI：10.1038/s41591-022-01689-3.
[19]	DEL NONNO F，FRUSTACI A，VERARDO R，et al. Virus-negative myopericarditis in human coronavirus infection: report from an autopsy series[J]. Circ Heart Fail，2020，13（11）：CIRCHEARTFAILURE120007636. DOI：10.1161/CIRCHEARTFAILURE.120.007636.
[20]	ESCHER F，PIETSCH H，ALESHCHEVA G，et al. Detection of viral SARS-CoV-2 genomes and histopathological changes in endomyocardial biopsies[J]. ESC Heart Fail，2020，7（5）：2440-2447. DOI：10.1002/ehf2.12805.
[21]	LINDNER D，FITZEK A，BRÄUNINGER H，et al. Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases[J]. JAMA Cardiol，2020，5（11）：1281-1285. DOI：10.1001/jamacardio.2020.3551.
[22]	BASSO C，LEONE O，RIZZO S，et al. Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study[J]. Eur Heart J，2020，41（39）：3827-3835. DOI：10.1093/eurheartj/ehaa664.
[23]	PERETTO G，SALA S，CAFORIO A L P. Acute myocardial injury，MINOCA，or myocarditis? Improving characterization of coronavirus-associated myocardial involvement[J]. Eur Heart J，2020，41（22）：2124-2125. DOI：10.1093/eurheartj/ehaa396.
[24]	VERMA A K，OLAGOKE O，MORENO J D，et al. SARS-CoV-2-associated myocarditis:a case of direct myocardial injury[J]. Circ Heart Fail，2022，15（3）：e008273. DOI：10.1161/CIRCHEARTFAILURE.120.008273.
[25]	AMMIRATI E，FRIGERIO M，ADLER E D，et al. Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document[J]. Circ Heart Fail，2020，13（11）：e007405. DOI：10.1161/CIRCHEARTFAILURE.120.007405.
[26]	MÜLLER M，COOPER L T，HEIDECKER B. Diagnosis，risk stratification and management of myocarditis[J]. Heart，2022，108（18）：1486-1497. DOI：10.1136/heartjnl-2021-319027.
[27]	中华医学会心血管病学分会精准医学学组，中华心血管病杂志编辑委员会，成人暴发性心肌炎工作组. 成人暴发性心肌炎诊断与治疗中国专家共识[J]. 中华心血管病杂志，2017，45（9）：742-752. DOI：10.3760/cma.j.issn.0253-3758.2017.09.004.
[28]	AMMIRATI E，CIPRIANI M，MORO C，et al. Clinical presentation and outcome in a contemporary cohort of patients with acute myocarditis: multicenter Lombardy registry[J]. Circulation，2018，138（11）：1088-1099. DOI：10.1161/CIRCULATIONAHA.118.035319.
[29]	PINTO-FILHO M M，PAIXÃO G M，GOMES P R，et al. Electrocardiographic findings and prognostic values in patients hospitalised with COVID-19 in the World Heart Federation Global Study[J]. Heart，2022：heartjnl-2022-321754. DOI：10.1136/heartjnl-2022-321754.
[30]	SZEKELY Y，LICHTER Y，TAIEB P，et al. Spectrum of cardiac manifestations in COVID-19: a systematic echocardiographic study[J]. Circulation，2020，142（4）：342-353. DOI：10.1161/CIRCULATIONAHA.120.047971.
[31]	KATO S，AZUMA M，FUKUI K，et al. Cardiac involvement in coronavirus disease 2019 assessed by cardiac magnetic resonance imaging：a meta-analysis[J]. Heart Vessels，2022，37（9）：1570-1582. DOI：10.1007/s00380-022-02055-6.
[32]	ARTICO J，SHIWANI H，MOON J C，et al. Myocardial involvement after hospitalization for COVID-19 complicated by troponin elevation：a prospective，multicenter，observational study[J]. Circulation，2023，147（5）：364-374. DOI：10.1161/CIRCULATIONAHA.122.060632.
[33]	PUNTMANN V O，MARTIN S，SHCHENDRYGINA A，et al. Long-term cardiac pathology in individuals with mild initial COVID-19 illness[J]. Nat Med，2022，28（10）：2117-2123. DOI：10.1038/s41591-022-02000-0.
[34]	RUBERG F L，BAGGISH A L，HAYS A G，et al. Utilization of cardiovascular magnetic resonance imaging for resumption of athletic activities following COVID-19 infection:an expert consensus document on behalf of the American Heart Association Council on Cardiovascular Radiology and Intervention Leadership and endorsed by the Society for Cardiovascular Magnetic Resonance[J]. Circ Cardiovasc Imaging，2023，16（1）：e014106. DOI：10.1161/CIRCIMAGING.122.014106.
[35]	CHEN B H，SHI N N，WU C W，et al. Early cardiac involvement in patients with acute COVID-19 infection identified by multiparametric cardiovascular magnetic resonance imaging[J]. Eur Heart J Cardiovasc Imaging，2021，22（8）：844-851. DOI：10.1093/ehjci/jeab042.
[36]	吕滨，任心爽，安云强，等. 中国心血管影像技术应用现状调查与医疗质量报告[J]. 中国循环杂志，2020，35（7）：625-633. DOI：10.3969/j.issn.1000-3614.2020.07.001.
[37]	GYÖNGYÖSI M，ALCAIDE P，ASSELBERGS F W，et al. Long COVID and the cardiovascular system—elucidating causes and cellular mechanisms in order to develop targeted diagnostic and therapeutic strategies：a joint Scientific Statement of the ESC Working Groups on Cellular Biology of the Heart and Myocardial and Pericardial Diseases[J]. Cardiovasc Res，2022: cvac115. DOI：10.1093/cvr/cvac115.
[38]	KOCIOL R D，COOPER L T，FANG J C，et al. Recognition and initial management of fulminant myocarditis: a scientific statement from the American heart association[J]. Circulation，2020，141（6）：e69-92. DOI：10.1161/CIR.0000000000000745.
[39]	中华人民共和国国家卫生健康委员会. 新型冠状病毒感染诊疗方案（试行第十版）[J]. 中华临床感染病杂志，2023，16（1）：1-9. DOI：10.3760/cma.j.issn.1674-2397.2023.01.001.
[40]	CHEN H S，WANG W，WU S N，et al. Corticosteroids for viral myocarditis[J]. Cochrane Database Syst Rev，2013，2013（10）：CD004471. DOI：10.1002/14651858.CD004471.pub3.
[41]	SAWALHA K，ABOZENAH M，KADADO A J，et al. Systematic review of COVID-19 related myocarditis: insights on management and outcome[J]. Cardiovasc Revasc Med，2021，23: 107-113. DOI：10.1016/j.carrev.2020.08.028.
[42]	KAMARULLAH W，NURCAHYANI，MARY JOSEPHINE C，et al. Corticosteroid therapy in management of myocarditis associated with COVID-19；a systematic review of current evidence[J]. Arch Acad Emerg Med，2021，9（1）：e32. DOI：10.22037/aaem.v9i1.1153.
[43]	ALTAY O，ARIF M，LI X Y，et al. Combined metabolic activators accelerates recovery in mild-to-moderate COVID-19[J]. Adv Sci（Weinh），2021，8（17）：e2101222. DOI：10.1002/advs.202101222.
[44]	杨德志，韩辉，陈桂. 辅酶Ⅰ治疗病毒性心肌炎患儿的临床疗效观察[J]. 内科，2018，13（4）：568-570，638. DOI：10.16121/j.cnki.cn45-1347/r.2018.04.09.
[45]	XIA G Z，QIN B W，MA C R，et al. High-dose vitamin C ameliorates cardiac injury in COVID-19 pandemic: a retrospective cohort study[J]. Aging（Albany NY），2021，13（17）：20906-20914. DOI：10.18632/aging.203503.
[46]	中华医学会心血管病学分会介入心脏病学组，中华医学会心血管病学分会动脉粥样硬化与冠心病学组，中国医师协会心血管内科医师分会血栓防治专业委员会，等. 稳定性冠心病诊断与治疗指南[J]. 中华心血管病杂志，2018，46（9）：680-694. DOI：10.3760/cma.j.issn.0253-3758.2018.09.004.
[47]	中国医师协会急诊医师分会，国家卫健委能力建设与继续教育中心急诊学专家委员会，中国医疗保健国际交流促进会急诊急救分会. 急性冠脉综合征急诊快速诊治指南（2019）[J]. 中华急诊医学杂志，2019，28（4）：421-428. DOI：10.3760/cma.j.issn.1671-0282.2019.04.003.
[48]	World Health Organization. Coronavirus disease（COVID-19）：post COVID-19 condition[EB/OL].（2021-12-16）[2023-01-30].
[49]	GREENHALGH T，KNIGHT M，A'COURT C，et al. Management of post-acute covid-19 in primary care[J]. BMJ，2020，370: m3026. DOI：10.1136/bmj.m3026.
[50]	National Institute for Health and Care Excellence（NICE），the Scottish Intercollegiate Guidelines Network（SIGN），the Royal College of General Practitioners（RCGP）. COVID-19 rapid guideline:managing the long-term effects of COVID-19[EB/OL].（2020-12-18）[2023-01-30].
[51]	Global Burden of Disease Long COVID Collaborators，WULF HANSON S，ABBAFATI C，et al. Estimated global proportions of individuals with persistent fatigue，cognitive，and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021[J]. JAMA，2022，328（16）：1604-1615. DOI：10.1001/jama.2022.18931.
[52]	BRYARLY M，PHILLIPS L T，FU Q，et al. Postural orthostatic tachycardia syndrome: JACC focus seminar[J]. J Am Coll Cardiol，2019，73（10）：1207-1228. DOI：10.1016/j.jacc.2018.11.059.
[53]	SUBRAMANIAN A，NIRANTHARAKUMAR K，HUGHES S，et al. Symptoms and risk factors for long COVID in non-hospitalized adults[J]. Nat Med，2022，28（8）：1706-1714. DOI：10.1038/s41591-022-01909-w.
[54]	HARBER M P，PETERMAN J E，IMBODEN M，et al. Cardiorespiratory fitness as a vital sign of CVD risk in the COVID-19 era[J]. Prog Cardiovasc Dis，2022：S0033-0620（22）00153-0. DOI：10.1016/j.pcad.2022.12.001.
[55]	MANDAL S，BARNETT J，BRILL S E，et al. 'Long-COVID': a cross-sectional study of persisting symptoms，biomarker and imaging abnormalities following hospitalisation for COVID-19[J]. Thorax，2021，76（4）：396-398. DOI：10.1136/thoraxjnl-2020-215818.
[56]	CROOK H，RAZA S，NOWELL J，et al. Long covid-mechanisms，risk factors，and management[J]. BMJ，2021，374：n1648. DOI：10.1136/bmj.n1648.
[57]	CASTANARES-ZAPATERO D，CHALON P，KOHN L，et al. Pathophysiology and mechanism of long COVID: a comprehensive review[J]. Ann Med，2022，54（1）：1473-1487. DOI：10.1080/07853890.2022.2076901.
[58]	SHIBATA S，FU Q，BIVENS T B，et al. Short-term exercise training improves the cardiovascular response to exercise in the postural orthostatic tachycardia syndrome[J]. J Physiol，2012，590（15）：3495-3505. DOI：10.1113/jphysiol.2012.233858.
[59]	LAI P H，LANCET E A，WEIDEN M D，et al. Characteristics associated with out-of-hospital cardiac arrests and resuscitations during the novel coronavirus disease 2019 pandemic in New York city[J]. JAMA Cardiol，2020，5（10）：1154-1163. DOI：10.1001/jamacardio.2020.2488.
[60]	MARIJON E，KARAM N，JOST D，et al. Out-of-hospital cardiac arrest during the COVID-19 pandemic in Paris，France: a population-based，observational study[J]. Lancet Public Health，2020，5（8）：e437-443. DOI：10.1016/S2468-2667(20)30117-1.
[61]	BALDI E，SECHI G M，MARE C，et al. Out-of-hospital cardiac arrest during the covid-19 outbreak in Italy[J]. N Engl J Med，2020，383（5）：496-498. DOI：10.1056/NEJMc2010418.
[62]	马成栋，吴秋萍，赵乾皓，等. 广东地区运动相关性猝死的流行病学调查[J]. 法医学杂志，2022，38（2）：246-253. DOI：10.12116/j.issn.1004-5619.2021.410908.
[63]	WAN E Y F，MATHUR S，ZHANG R，et al. Association of COVID-19 with short- and long-term risk of cardiovascular disease and mortality: a prospective cohort in UK Biobank[J]. Cardiovasc Res，2023：cvac195. DOI：10.1093/cvr/cvac195.
[64]	MOHAMED M O，BANERJEE A. Long COVID and cardiovascular disease: a learning health system approach[J]. Nat Rev Cardiol，2022，19（5）：287-288. DOI：10.1038/s41569-022-00697-7.
[65]	李建军. 血脂异常与动脉粥样硬化关系的现代观念[J]. 中国循环杂志，2022，37（3）：212-214. DOI：10.3969/j.issn.1000-3614.2022.03.002.
[66]	ZANOLI L，BRIET M，EMPANA J P，et al. Vascular consequences of inflammation: a position statement from the ESH Working Group on Vascular Structure and Function and the ARTERY Society[J]. J Hypertens，2020，38（9）：1682-1698. DOI：10.1097/hjh.0000000000002508.
[67]	ABBASI J. The COVID heart-one year after SARS-CoV-2 infection，patients have an array of increased cardiovascular risks[J]. JAMA，2022，327（12）：1113-1114. DOI：10.1001/jama.2022.2411.
[68]	HU Y Z，SUN Z J，YU C Q，et al. Association between pneumonia hospitalisation and long-term risk of cardiovascular disease in Chinese adults: a prospective cohort study[J]. EClinicalMedicine，2023，55: 101761. DOI：10.1016/j.eclinm.2022.101761.
[69]	DALE C E，TAKHAR R，CARRAGHER R，et al. The impact of the COVID-19 pandemic on cardiovascular disease prevention and management[J]. Nat Med，2023，29（1）：219-225. DOI：10.1038/s41591-022-02158-7.
[70]	世界卫生组织欧洲区域办事处. 康复指导手册：COVID-19相关疾病的自我管理，第二版[DB/OL].（2021-11-29）[2023-01-30].
[71]	ZHU Y T，WANG Z M，ZHOU Y，et al. Summary of respiratory rehabilitation and physical therapy guidelines for patients with COVID-19 based on recommendations of World Confederation for Physical Therapy and National Association of Physical Therapy[J]. J Phys Ther Sci，2020，32（8）：545-549. DOI：10.1589/jpts.32.545.
[72]	SCHMIDT T，BJARNASON-WEHRENS B，ZACHER J，et al. Sports，myocarditis and COVID-19: diagnostics，prevention and return-to-play strategies[J]. Int J Sports Med，2022，43（13）：1097-1105. DOI：10.1055/a-1810-5314.
[73]	BARAZZONI R，BISCHOFF S C，BREDA J，et al. ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection[J]. Clin Nutr，2020，39（6）：1631-1638. DOI：10.1016/j.clnu.2020.03.022.
[74]	WORLD PHYSIOTHERAPY. Safe rehabilitation approaches for people living with Long COVID: physical activity and exercise[EB/OL].[2023-01-30].

新型冠状病毒感染相关心肌损伤、心肌炎和感染后状态管理专家共识（第二版）

Expert Consensus for Management of Myocardial Injury, Myocarditis, and Post-infection Condition with Coronavirus Disease 2019 (Second Edition)

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 2

参考文献 74

相关文章 15

编辑推荐

Metrics

留言

[1]	陈典, 隆寰宇, 褚岚和, 姜奕夏, 郭万金, 牛杨, 陈亚红. 2026年GOLD慢性阻塞性肺疾病诊断、治疗、管理及预防全球策略更新要点解读[J]. 中国全科医学, 2026, 29(21): 2913-2932.
[2]	陈向阳, 黄红梅, 李舍予. 成人肥胖的预防与管理：从六大关键词看2025年度进展与趋势[J]. 中国全科医学, 2026, 29(20): 2753-2758.
[3]	中国药理学会药源性疾病专委会. 酸相关疾病药物治疗专家共识[J]. 中国全科医学, 2026, 29(19): 2593-2607.
[4]	陈义萍, 张剑梅, 厉彦虎, 李睿, 张瑞平, 杨萍. COVID-19后遗症心肌损伤的诊疗进展[J]. 中国全科医学, 2026, 29(18): 2585-2592.
[5]	黑墨然, 马慧娥, 徐泽成, 闫世艳, 李紫岩, 杨毅, 金军, 陈泽林, 郭义, 赵雪, 赵天易. 国内外临床实践指南研制手册中临床问题确定方法的比较、分析及思考[J]. 中国全科医学, 2026, 29(18): 2554-2560.
[6]	海峡两岸医药卫生交流协会全科医学分会, 浙江省医学会全科医学分会, 浙江省数理医学学会全科未分化疾病专委会, 中国老年医学学会. 麻木诊治与管理专家共识（2025）[J]. 中国全科医学, 2026, 29(18): 2433-2449.
[7]	范梅香, 闫云云, 黄延焱. 澳大利亚全科医生学会《全科医学的预防活动指南》解读与讨论：膀胱癌的预防[J]. 中国全科医学, 2026, 29(18): 2450-2453.
[8]	王奕博, 何凯羽, 梁国芬, 杨振华, 赵庭贤, 廖碧仪, 张腊, 刘世巍, 龚学忠, 刘旭生, 古月瑜, 秦新东, 苏国彬. 女性复发性尿路感染的诊断与管理：基于现有指南的对比与解读[J]. 中国全科医学, 2026, 29(17): 2387-2399.
[9]	童敏, 王颖, 徐衍燊, 曾永渐, 文华, 刘学, 孙香娟, 张丰华. 功能性消化不良指南质量评价：基于AGREE Ⅱ和RIGHT工具[J]. 中国全科医学, 2026, 29(17): 2410-2417.
[10]	孟紫曦, 赵慧朵, 刘瑞东, 王蓓蓓, 姜明强, 程旭锋. 急性乳腺炎中西医结合诊疗指南[J]. 中国全科医学, 2026, 29(17): 2273-2281.
[11]	中国营养学会肥胖防控分会. 中国肥胖行为与生活方式干预指南[J]. 中国全科医学, 2026, 29(16): 2113-2139.
[12]	郭娇, 张高静, 刘新灿. 中医药临床实践指南/共识的质量评价：基于两种指南评价工具[J]. 中国全科医学, 2026, 29(15): 2100-2106.
[13]	中华中医药学会肾病分会, 广东省中医药学会肾病专业委员会, 苏佩玲, 杨丽虹, 包崑. 特发性膜性肾病中西医结合诊疗指南（2025）[J]. 中国全科医学, 2026, 29(15): 1953-1970.
[14]	刘晓羽, 朱荣欣, 张博, 苏杭, 任献青. 基于改良德尔菲法构建《儿童遗尿症中西医结合诊疗指南》临床问题及结局指标[J]. 中国全科医学, 2026, 29(15): 2050-2055.
[15]	中国康复医学会社区康复工作委员会. 认知障碍患者居家康复管理的中国专家共识（2026版）[J]. 中国全科医学, 2026, 29(14): 1793-1802.